Project Grant R01AI182111
Award Date
7/25/25
Completion Date
6/30/30
Dollars Obligated
$560K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $479,730 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Wisconsin - Madison. The 5-year grant, effective from December 1, 2024 to November 30, 2029, will support research to elucidate the mechanisms by which prophages (viral DNA) in the gut symbiont Limosilactobacilus reuteri modulate the production of the antimicrobial compound reuterin. The research aims to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $267,310 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Illinois in Chicago. The grant, awarded on August 27, 2024, supports research to evaluate the role of a lipoic acid transfer protein in Staphylococcus aureus metabolism and virulence. The project aims to determine how this lipoic acid transfer protein interfaces with other metabolic enzymes to control...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $390,000 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Colorado-Denver. The 5-year grant, which commenced on May 2, 2025, supports research to investigate the molecular basis of how the bacterial pathogen Staphylococcus aureus uses its unique serine protease-like (Spl) enzymes, particularly the Spl B variant, to manipulate host cell processes during infection....
This Project Grant award of $2,841,668.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research focused on understanding how the bacterial enzyme SagB in Staphylococcus aureus (S. aureus) modulates the host immune response and promotes infection. The key goals are to determine how SagB-modified peptidoglycan is recognized by immune cells, investigate the mechanism of SagB-dependent IL-1β...
This $3,021,822 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by Georgetown University to investigate the role of branched-chain fatty acids in the physiology and virulence of Staphylococcus aureus, a leading cause of skin and soft tissue infections. The research aims to: 1) determine the pathway by which S. aureus salvages and synthesizes branched-chain fatty...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $173,030 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to President and Fellows of Harvard College. The grant, awarded on September 25, 2024, will fund the development of a novel assay for targeted isolation of environmental bacteriophages (phages) based on their receptor dependencies. The project aims to create a generalizable technique that allows selecting phages that require...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $369,431 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Wisconsin-Eau Claire. The grant, awarded on August 21, 2024, supports a project titled "Molecular Determinants and Behavioral Fingerprints of Schistosome Miracidia Host-Seeking". The project aims to quantitatively describe the host-seeking behaviors of schistosome miracidia, the aquatic larval...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $160,095 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to St. Jude Children's Research Hospital Inc. in Memphis, TN. The grant supports research to determine how the presence of mucin, a key component of mucus, inhibits autolysis (self-destruction) of the pathogenic bacterium Streptococcus pneumoniae. The research aims to understand how mucin promotes prolonged survival of...
The University of Kansas Medical Center Research Institute, Inc. (KUMCRI) was awarded a $677,325 federal Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) from the National Institute of Allergy and Infectious Diseases (NIAID). The 5-year grant, effective from August 1, 2025 to July 31, 2030, will support research to understand the mechanisms by which the bacterium Staphylococcus aureus utilizes exogenous fatty acids. The key objectives include: Elucidating...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $453,750 to Tufts University School of Medicine to study how certain bacteriophages (viruses that infect bacteria) evade the protective mechanisms of bacteria, including some deadly pathogens like Vibrio cholerae. The project aims to determine the counter-defense mechanisms used by these phages and identify the...